Human Prostate Adenocarcinoma Epithelial Cell LNCAP Transfection Kit

Modes of administration

Reagent exhibits at least 85% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.

Description

The LNCaP human prostate adenocarcinoma epithelial cell line is a valuable tool in the field of clinical oncology research due to its origin from a Caucasian male's supraclavicular lymph node metastasis in 1977. This cell line has the ability to grow in aggregates or as single cells, forming clones and exhibiting resistance to human fibroblast interferon. Furthermore, LNCaP cells are receptive to hormones and exhibit a high affinity for androgen receptors in both cytosolic and nuclear fractions of cells. Notably, LNCaP cells express prostate-specific antigen, and estrogen receptors are detectable in the cytosol. Tumor development frequency and appearance time differ significantly between male and female mice, with male mice exhibiting a higher incidence and earlier onset of tumors. Hormonal manipulations demonstrate that tumor development correlates with serum androgen levels, but the rate of tumor growth is independent of gender or hormonal status. CD BioSciences offers nanoparticle-based transfection reagent kits specifically optimized for use with the LNCaP cell line, facilitating drug discovery and various biomedical applications.